Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay

Aim: The QuantiGene2.0 Assay Has Low Interlaboratory Variability and Can Directly Meas. RNA Levels Without A Reverse Transcription Step or A Polymerase Chain Reaction Proc.. to Evaluate the Utility of the QuantiGene2.0 Assay for the Assess. of Oestrogen Receptor and Progesterone Receptor Status As An Alternative to Immunohistochemistry , We Compared Dis.-free Survival Acc. to Quantit. ER and PR Measurements When Using IHC and the QuantiGene2.0 Assay. Methods: Samples Were Collected from 171 Patients Who Underwent Breast Cancer Surg. between January 2003 and December 2006. Cox Proportional Hazard Anal. Was Performed and Concordance between IHC and the QuantiGene2.0 Assay for the Assess. of ER and PR Status Was Evaluated. Results: ER and PR Assessments Were Well Correlated between IHC and the QuantiGene2.0 Assay. the Difference in Dis.-free Survival Was Statistically Significant Acc. to Expression of PR, but Not ER, between the Two Groups. Conclusions: the QuantiGene2.0 Assay Showed Results Similar to Those of IHC for the Assess. of ER and PR in Response to Treatm.. Therefore, Our Data Suggest That the QuantiGene2.0 Assay Can Be Used to Determine ER and PR Status and Corroborate IHC Findings, Which at Present Are Considered As the Std. for the Eval. of ER and PR Status.